Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. (30th September 2022)

• Record Type: Journal Article
• Authors: Darlow, Christopher A; McEntee, Laura; Johnson, Adam; Farrington, Nicola; Unsworth, Jennifer; Jimenez-Valverde, Ana; Jagota, Bhavana; Kolamunnage-Dona, Ruwanthi; Da Costa, Renata M A; Ellis, Sally; Franceschi, François; Sharland, Mike; Neely, Michael; Piddock, Laura; Das, Shampa; Hope, William
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 77:Number 12(2022)
• Page Start: 3349
• Page End: 3357
• Publication Date: 2022-09-30
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkac323
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Background: Annual mortality from neonatal sepsis is an estimated 430 000–680 000 infants globally, most of which occur in low- and middle-income countries (LMICs). The WHO currently recommends a narrow-spectrum β-lactam (e.g. ampicillin) and gentamicin as first-line empirical therapy. However, available epidemiological data demonstrate high rates of resistance to both agents. Alternative empirical regimens are needed. Flomoxef and amikacin are two off-patent antibiotics with potential for use in this setting. Objectives: To assess the pharmacodynamics of flomoxef and amikacin in combination. Methods: The pharmacodynamic interaction of flomoxef and amikacin was assessed in chequerboard assays and a 16-arm dose-ranged hollow-fibre infection model (HFIM) experiment. The combination was further assessed in HFIM experiments mimicking neonatal plasma exposures of clinically relevant doses of both drugs against five Enterobacterales isolates with a range of flomoxef/amikacin MICs. Results: Flomoxef and amikacin in combination were synergistic in bacterial killing in both assays and prevention of emergence of amikacin resistance in the HFIM. In the HFIM assessing neonatal-like drug exposures, the combination killed 3/5 strains to sterility, (including 2/5 that monotherapy with either drug failed to kill) and failed to kill the 2/5 strains with flomoxef MICs of 32 mg/L. Conclusions: We conclude that the combination of flomoxef and amikacin is synergistic and is a potentially clinically effective regimen for the empirical treatment of neonatal sepsis in LMIC settings and is therefore suitable for further assessment in a clinical trial.